About Us       Blog       Clients       Disclaimer       Market Basics       Partners       Quotes & News       Video       Contact Us
The QualityStocks Daily Newsletter for Thursday, July 27th, 2017

The QualityStocks
Daily Stock List


OWC Pharmaceutical Research Corp. (OWCP)

CFN Media Group, Promotion Stock Secrets, and Cannabis Financial Network News reported previously on OWC Pharmaceutical Research Corp. (OWCP), and today we report on the Company, here at the QualityStocks Daily Newsletter.

OWC Pharmaceutical Research Corp. engages in the research and development (R&D) of cannabis-based medical products. The OTCQB-listed Company provides medical products for the treatment of diverse medical conditions and/or diseases. These include multiple myeloma, psoriasis, PTSD, and migraines; as well as delivery systems. One World Cannabis Ltd. is a wholly-owned subsidiary of OWC Pharmaceutical Research. OWC has its corporate head office in Petach Tikva, Israel.

One World Cannabis’ Research Division centers on pursuing clinical trials evaluating the effectiveness of cannabinoids in the treatment of different medical conditions. Its Consulting Division’s dedication is to helping governments and companies navigate complex global cannabis regulatory frameworks. A medical cannabis R&D business, all of the Company’s research occurs at foremost Israeli hospitals and scientific institutions, and are led by internationally distinguished investigators.

OWC Pharmaceutical Research has entered into research and collaboration agreements with three of the leading research institutions in Israel. These include Sheba Academic Medical Center, one of the top academic hospitals in the Middle East. These agreements serve as the foundation for the Company’s clinical trials. They ensure that all of its studies have been, and will continue to be, based on established research protocols of the U.S. Food and Drug Administration (FDA), Institutional Review Boards, and Independent Ethical Committees.

OWC Pharmaceutical Research has completed the development of a proprietary, cannabinoid-enriched sublingual tablet for the administration of medical cannabis. The technology behind the tablet is protected. It provides for the ingestion of almost any dosage of medical cannabis with a sublingual delivery mechanism, where the compounds are absorbed directly into the patient's blood by way of oral epithelial tissue.

Recently, OWC Pharmaceutical Research and mediq Innovation Partners (Frankfurt, Germany) announced an agreement for the introduction of OWC's active cannabinoid-based topical psoriasis cream to the German market. mediq has wide-ranging experience, knowledge, and a successful record of accomplishment in enabling Israel-based companies to penetrate the European markets. mediq's goals for OWC Pharmaceutical Research will comprise scientific collaboration and most importantly the development of a commercial market for OWC's proprietary, active cannabinoid-based topical psoriasis cream in Germany.

In late June, OWC Pharmaceutical Research announced that its wholly-owned, Israel-based subsidiary, One World Cannabis filed a patent application with the United States Patent and Trademark Office (USPTO) for its active cannabinoid-based topical cream. The new patent application follows the earlier filed 'provisional' patent application. The added protection that this patent application provides for the Company’s intellectual property (IP) will enable it to speed up its continuing discussions and negotiations concerning scientific, medical, and commercial collaboration.

This week, OWC Pharmaceutical Research announced the appointment of Dr. Stanley Hirsch as its active Chairman of the Board of Directors. Dr. Hirsch has had broad scientific, executive, and Board level experience for over the past 25 years in private and publicly listed companies in biopharmaceutical and agricultural biotechnology industries, among others. This includes direct experience in raising capital and leading Mergers & Acquisition (M&A) activity together with multi-cultural management skills. He has managed companies in Israel, Brazil, the United Kingdom, China and the U.S.

OWC Pharmaceutical Research Corp. (OWCP), closed Thursday's trading session at $0.342, down 10.00%, on 3,216,725 volume with 754 trades. The average volume for the last 60 days is 922,513 and the stock's 52-week low/high is $0.003/$3.23.

Cannabics Pharmaceuticals, Inc. (CNBX)

StreetAuthority Daily, Wall Street Daily, TopPennyStockMovers, Stockgoodies, Promotion Stock Secrets, Wealth Insider Alert, Wall Street Mover, Market Intelligence Center, SmallCapVoice, Cannabis Financial Network News, and TheMicrocapNews reported previously on Cannabics Pharmaceuticals, Inc. (CNBX), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Cannabics Pharmaceuticals, Inc.’s devotion is to the development of advanced cannabinoid-based treatments and therapies. Its primary emphasis is the development of novel therapies and biotechnological tools designed to provide relief from diverse ailments and treat human malignancies. The Company’s’ vision is to create individually tailored natural therapies for cancer patients, employing advanced screening systems and personalized bioinformatics tools. OTCQB-listed, Cannabics Pharmaceuticals is based in Bethesda, Maryland.

Cannabics has licensed Research and Development (R&D) based in Israel. This R&D’s dedication is to the development of palliative and personalized anti-cancer treatments channelling the multipurpose therapeutic values of cannabinoids to create tailored therapies for cancer patients. The Company’s integrated technology has created a successful medically standardized delivery system providing patients natural, reliable, and safe therapy.

Cannabics Pharmaceuticals’ advanced tools include novel delivery systems, personalized medicine diagnostics, and therapies grounded on cannabinoid compounds. Its principal technology is Cannabics SR. This is a technology for a long acting oil capsule that provides a safe, effective, and reliable administration of cannabis. The technology’s composition is exclusively from food grade materials.

At the end of June, Cannabics Pharmaceuticals announced it received positive results from screening necrosis (cell death) of circulating tumor cells, from cancer patients, treated with the cannabinoids CBD and CBDA. The results greatly strengthen its earlier accumulated data on cannabinoid anti-tumor activity. Furthermore, the screening results that indicate varied effectiveness of the tested cannabinoids upon diverse tumors (colon, breast, prostate) reaffirm the use of the Company’s proprietary technology in providing supportive data for personalized treatments.

Earlier this month, Cannabics Pharmaceuticals announced it executed a Collaboration Agreement with SIMFO GmbH. Under the Agreement, the Company shall be the exclusive worldwide provider of SIMFO's CTC diagnostics to cancer patients treated with natural cannabinoids. The diagnostics include a count of circulating tumor cells (CTC) and drug sensitivity tests of different cannabinoids, for example THC, THCA, CBD, and CBDA. SIMFO (located in Germany) is an international leader in cancer diagnostics and liquid biopsies.

This week, Cannabics Pharmaceuticals announced it established a Genetic lab, which will develop diagnostic tools based on human genome, tumor genetics, as well as cannabinoids. Cannabics recruited Dr. Moran Grinberg to serve as its VP of R&D and to lead the Genetic research. Dr. Grinberg has a PhD in Virology and MSc in clinical pharmacology with extensive experience in conceptualizing and executing pharmacological research.

Cannabics Pharmaceuticals, Inc. (CNBX), closed Thursday's trading session at $1.266, down 9.57%, on 625,048 volume with 613 trades. The average volume for the last 60 days is 495,696 and the stock's 52-week low/high is $0.035/$7.60.

BioCorRx, Inc. (BICX)

MassiveStockProfits, BUYINS.NET, OTPicks, Damn Good Penny Picks, Equity Observer, SmallCapVoice, Value Penny Stocks, Penny Stock Newsletter, PREPUMP STOCKS, Penny Picks, and PennyStocks24 reported earlier on BioCorRx, Inc. (BICX), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

BioCorRx, Inc. is a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions. It provides a unique approach to the treatment of substance abuse addiction and has its BioCorRx® Recovery Program. BioCorRx’s concentration is on improving the quality of life for recovering addicts. The Company is based in Anaheim, California and lists on the OTCQB.

The BioCorRx® Recovery Program is a non-addictive, medication-assisted treatment (MAT) program. The program consists of two chief components. The first component consists of an outpatient implant procedure performed by a licensed physician. The implant delivers the non-addictive medicine, naltrexone, an opioid antagonist, which can substantially lessen physical cravings for alcohol and opioids.

The second component is a one-on-one proprietary counseling program. It is specifically tailored for the treatment of alcoholism and other substance abuse addictions for those receiving long-term naltrexone treatment.

In addition, the Company has expanded the support structure to include 12 months of a peer-support system employing trained recovery specialists. Moreover, BioCorRx’ is developing a patent pending injectable form of naltrexone.

BioCorRx also has a research and development (R&D) subsidiary, BioCorRx Pharmaceuticals. Presently, this subsidiary is developing a new injectable naltrexone technology (BICX101) through a partnership with TheraKine Ltd. BioCorRx’s intention is to seek Food and Drug Administration (FDA) approval for BICX101 and/or its naltrexone implant product(s). BICX101 is a sustained release, injectable naltrexone for the treatment of opioid abuse and alcoholism.

Recently, BioCorRx announced it has partnered with the Virtual Reality Medical Center (VRMC), led by Drs. Mark and Brenda Wiederhold, and Dr. Joseph Shurman, Co-Director of the Pain and Palliative Care Committee at Scripps Memorial Hospital in La Jolla, California, to conduct a study on the BioCorRx Recovery Program and BioCorRx’s long lasting naltrexone implant. VRMC’s plan is to conduct studies at its office in the Scripps Memorial Hospital Campus where they have access to the expertise and experience of the Scripps physicians and community. Drs. Mark and Brenda Wiederhold will be working closely with Dr. Joseph Shurman.

Last week, BioCorRx announced that Hope Recovery and Wellness in West Palm Beach, Florida will implement the BioCorRx Recovery Program in their facility in Day/Night and IOP (intensive outpatient) setting. Hope Recovery and Wellness is the first center to implement the BioCorRx Recovery Program in this region of Florida.  

Furthermore, this week, BioCorRx announced that EnLite™ Clinics will implement the BioCorRx Recovery Program in three of its locations in Ohio. EnLite™ Clinics is the first group of centers in Ohio to implement the BioCorRx Recovery Program. EnLite™ Clinics provides a Suboxone Detox and Maintenance treatment program. Since 2006, EnLite™ Clinics has been providing confidential treatment and promoting recovery to its patients.

BioCorRx, Inc. (BICX), closed Thursday's trading session at $0.1099, up 15.68%, on 588,753 volume with 43 trades. The average volume for the last 60 days is 588,687 and the stock's 52-week low/high is $0.01/$0.34.

Intelligent Cloud Resources, Inc. (ITLL)

US Financial News Today, 4 Traders, Business Wire, and Market Exclusive reported on Intelligent Cloud Resources, Inc. (ITLL), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

Intelligent Cloud Resources, Inc. has been working to provide cloud enabler and cloud broker services to small and medium sized organizations in Canada. In addition, the Company’s plan is to expand to such organizations in the United States. It announced on January 25, 2017, that its common stock started trading on the OTC Markets Group’s OTCQB. Intelligent Cloud Resources has its corporate headquarters in Kansas City, Missouri.

The Fonia "All Access Mobile" is an end-to-end Mobile solution. Intelligent Cloud Resources said that the launch of the Fonia “All Access Mobile” platform will be a strong consumer oriented addition to its product offering. It mainly works to serve individuals, regardless of their credit score, via an MVNO (Mobile Virtual Network Operator) Fonia Mobile (and Fonia Financial). The service will bundle a traditional handset sale with a hybrid phone rate plan (a mix of prepaid and postpaid plans) and a prepaid MasterCard.

Fonia offers phones and plans with its Fonia “All Access Mobile”. Also, all subscribers receive a premium MasterCard. A user of Fonia can obtain another 30-day no-contract plan, as well as save time with Auto-Refill. The Company shares networks with the four top carriers. A customer can activate with a new number. Furthermore, a customer can activate and transfer their number.

In December of 2016, Intelligent Cloud Resources announced an agreement to obtain a perpetual license to provide Leagoo Smart Phones and the innovative Fonia "All Access Mobile" platform to the territory of Florida.

Last week, Intelligent Cloud Resources announced the successful completion of the earlier announced acquisition of the innovative Fonia “All Access Mobile” platform perpetual license and premier Leagoo Smart Phones for the territory of Florida. This will be the initial step in a program to launch the product and service in numerous territories.

Mr. Christopher Pay, Director of Intelligent Cloud Resources, said “Today is a historic moment for us. The closing of this transaction opens the door to create substantial growth opportunities and deliver even greater benefits for our customers. We are excited to have completed the transaction which provides compelling value to our stockholders, benefits our customers and provides new opportunities for our employees."

Intelligent Cloud Resources, Inc. (ITLL), closed Thursday's trading session at $0.957, up 10.64%, on 332,547 volume with 119 trades. The average volume for the last 60 days is 18,007 and the stock's 52-week low/high is $0.1027/$2.50.

Liberty One Lithium Corp. (LRTTF)

OTC Markets, ProcativeInvestors, 4 Traders, and MarketWatch reported on Liberty One Lithium Corp. (LRTTF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Liberty One Lithium Corp. is a developing exploration company based in Vancouver, British Columbia. It centers on the acquisition and development of high grade lithium brine deposits. Lithium is an important component of batteries, which power everything from cars to smartphones, laptops, and power tools. The Company sees lithium as an opportunity to participate in the diversification and continued growth (and protection) of a strong worldwide energy policy. Liberty One Lithium’s shares trade on the OTC Markets Group’s OTCQB.

The Company’s initial prospects are in Argentina’s “Lithium Triangle” and Utah’s Paradox Basin. They are situated in historic sources of high grade lithium-bearing brines. Historic resource indicates potential to produce huge volumes of brine on-site.

In Argentina, the Company’s Pocitos West prospect comprises more than 39,000 acres (15,857 Ha) in the middle of the well-known lithium triangle. It is in the Pocitos Salar, Los Andes Department, Western Salta Province, Argentina.

In Utah, Liberty One Lithium’s North Paradox property comprises 233 placer claims covering 4,480 acres situated upon the Paradox Basin in Grand County, Utah, 15 kilometers west of the town of Moab, in southeastern Utah.

Last month, Liberty One Lithium announced the closing of a mineral option and joint venture (JV) agreement with Millennial Lithium Corp. (Vancouver, British Coloumbia). This agreement grants Liberty One Lithium the sole and exclusive right and option to acquire up to an 80 percent undivided beneficial right, title, and interest in the Pocitos West project in Argentina.

This month, Liberty One Lithium announced plans for a geophysical survey at its JV interest in the Pocitos West Project in Argentina. Liberty One Lithium, by way of Millennial Lithium, has contracted Salta based Tecnología y Recursos (TyR) to conduct a geophysical survey at Pocitos West. TyR will conduct a Vertical Electrical Soundings (VES) survey that detects variations in subsurface conductivity.

This week, Liberty One Lithium announced the appointment of Mr. Brad Nichol, P. Eng., MBA to the position of Chief Executive Officer (CEO) and President of the Company. Mr. Nichol is a global entrepreneur. He has served and advised corporations on strategy and finance for more than25 years. Throughout his career he has served as Senior Executive and Director of several public and private enterprises across the finance and resource sectors. 

Liberty One Lithium Corp. (LRTTF), closed Thursday's trading session at $0.5391, down 2.20%, on 426,289 volume with 208 trades. The average volume for the last 60 days is 135,983 and the stock's 52-week low/high is $0.3739/$0.5899.


The QualityStocks
Company Corner


InMed Pharmaceuticals, Inc. (IMLFF)

The QualityStocks Daily Newsletter would like to spotlight InMed Pharmaceuticals, Inc. (IMLFF). Today, InMed Pharmaceuticals, Inc. closed trading at $0.265, off by 2.57%, on 264,509 volume with 150 trades. The stock’s average daily volume over the past 60 days is 389,165, and its 52-week low/high is $0.0501/$0.72.

InMed Pharmaceuticals, Inc. announced today the publication of company-sponsored research in the European Journal of Pain. The article, titled "Delta-9-tetrahydrocannabinol decreases masticatory muscle sensitization in female rats through peripheral cannabinoid receptor activation", presents results from a study co-sponsored by InMed and the MITACS Elevate Postdoctoral Fellowship program. The study was conducted by Dr. Hayes Wong and Prof. Brian Cairns at the University of British Columbia and was co-authored by Dr. Sazzad Hossain, Chief Scientific Officer of InMed.

InMed Pharmaceuticals, Inc. (IMLFF) is a preclinical-stage biopharmaceutical company specializing in the development of novel therapeutics leveraging the pharmacological benefits of cannabinoids. Utilizing its proprietary bioinformatics assessment tool, InMed aims to identify bioactive compounds found within the cannabis plant that have the potential to offer optimized therapeutic benefit while demonstrating limited adverse effects. This assessment tool, in combination with the company’s cannabinoid biosynthesis technology and drug development pipeline, serves as InMed’s fundamental value driver.

Bioinformatics is a proprietary, computer-based program designed to assist in the identification of novel cannabinoids using comprehensive algorithms to integrate data from numerous bioinformatics databases, as well as a database on the structure of currently approved pharmaceutical products and an extensive database on over 90 individual cannabinoid drugs found in cannabis. This extensive collection of data is derived from both public and propriety-based sources. Leveraging this tool, the company aims to create associations between approved pharmaceuticals and cannabinoids with similar structures in order to identify active cannabinoids that have the potential to treat specific diseases. Per InMed’s website, this type of bioinformatics assessment represents “significant promise for future drug discovery, as it integrates many data sets and builds holistic models to approach a specific disease.”

After discovering these promising active cannabinoids, InMed moves to test and confirm their activity in biological systems through in vitro and in vivo experimentation. It is at this stage of development that the company’s proprietary biosynthesis process of cannabinoid manufacturing will be most promising. InMed is currently developing a robust, high-yield biosynthesis process for manufacturing all 90+ naturally-occurring cannabinoids. By modifying the agriculture-based formula for harvesting cannabinoids, InMed aims to combine the inherent safety and known efficacy of the natural drug structure with the convenience, control and quality of 21st Century laboratory-based manufacturing processes.

The company’s pipeline currently includes two drug candidates in preclinical development, including INM-750 for the treatment of epidermolysis bullosa (EB) and INM-085 for the treatment of glaucoma. Referred to by the Dystrophic Epidermolysis Bullosa Research Association of America as “The Worst Disease You’ve Never Heard Of,” EB is a rare genetic connective tissue disorder that affects roughly one out of every 20,000 births in the United States. The condition currently has no approved treatment or cure. Through the development of INM-750, InMed is attempting to address this significant unmet medical need. The drug candidate replaces missing keratins in the skin with specially selected cannabinoids in an effort to modulate the painful manifestations of EB.

INM-085, InMed’s second development candidate, is formulated to reduce the elevated intra-ocular pressure that is often associated with glaucoma. Additionally, the cannabinoids utilized in INM-085 are expected to provide neuroprotection for the retinal ganglion cells and other optic nerve tissues following topical administration. Although it is still in preclinical development, INM-085 targets a sizable market. According to the Glaucoma Research Foundation, glaucoma is a leading cause of blindness with no approved cure. The National Institutes of Health estimates that more than 3 million Americans currently have glaucoma, and more than 120,000 have been blinded by the disease.

InMed is focused on progressing toward validation of its drug candidate selection, using data to secure its patents and developing key disruptive technologies. In 2016, the company was successful in completing financings of $1.9 million. In January 2017, InMed completed a non-brokered private placement of common shares generating aggregate gross proceeds of C$1.5 million, strongly positioning the company to attract the new investment required to fund its aggressive growth strategies in 2017.

The company’s management team has well over a century of combined experience in the biopharmaceutical space. Company CEO Eric Adams has more than 25 years of experience in company and capital formation, global market development, mergers and acquisitions, licensing and corporate governance. During his time as CEO of enGene Inc., he led the gene therapy startup to a position at the head of the industry.

Joining Adams on the InMed management team are Chief Scientific Officer Dr. Sazzan Hossain; Senior Vice President, Clinical and Regulatory Affairs Alexandra D.J. Mancini; SVP, Corporate Strategy & Investor Relations Chris Bogart; and Chief Financial Officer Jeff Charpentier, as well as Chief Medical Officer Dr. Ado Muhammed, MD, DPM, MFPM.

Muhammed, in particular, has an extensive history in the pharmaceutical industry, having previously served as an executive of GW Pharmaceuticals, a global leader in the development of cannabinoid-based medicines. During his time as Associate Medical Director of that company, Muhammed played an instrumental role in the development and FDA approval of one of the first cannabis drugs. This GW Pharmaceuticals development program coincided with a sharp rise in share price from less than $9 in 2013 to more than $129 today, with the company’s current market value totaling more than $2.9 billion. Disclaimer

InMed Pharmaceuticals, Inc. Company Blog

InMed Pharmaceuticals, Inc. News:

InMed Announces Publication in European Journal of Pain

InMed Pharma Advances Cannabinoid EB Therapy -- CFN Media

InMed Signs R&D Agreement with ATERA

Singlepoint, Inc. (SING)

The QualityStocks Daily Newsletter would like to spotlight Singlepoint, Inc. (SING). Today, Singlepoint, Inc. closed trading at $0.0282, up 29.36%, on 18,460,065 volume with 820 trades. The stock’s average daily volume over the past 60 days is 8,715,033, and its 52-week low/high is $0.0075/$0.142.

Singlepoint, Inc. (SING) has grown from a full-service mobile technology provider to a publicly-traded holding company. Through diversification into horizontal markets, SinglePoint is building its portfolio by acquiring an interest in undervalued subsidiaries, thereby providing a rich, diversified holding base.

SinglePoint's approach is to first research and identify acquisition opportunities in which it can take an active and influential role among existing leadership to provide enhanced strategy and direction. Target companies are undervalued, cash-flow positive, with high potential and verified assets. SinglePoint acquires and takes controlling interest of successful candidate companies.

SinglePoint recently signed a Letter of Intent to acquire an interest in Jacksam Corp., dba Convectium, a profitable California-based provider of equipment, branding, and packaging solutions for the cannabis industry. Convectium has developed the world's first cartridge and vape pen oil filling machine for wholesale distribution to dispensaries. The 710Shark and 710Seal systems can fill and package over 100 cartridges or disposable vape pens in 30 seconds and are sold to dispensaries through its EquipCanna.com brand. The company also operates a consumer brand that includes BlackoutX and HazeSticks and reaches customers in over 52 countries.

Additionally, SinglePoint has raised more than $300,000 and has signed a Letter of Intent to secure an additional $1 million in funding. The move provides management with ample capital to execute its business plan, while avoiding debt repayments that can eat into cash flow and reduce flexibility over time. It's also a rare development for a development-stage company in the cannabis industry.

Guided by a visionary leadership team with extensive experience in technology, engineering, marketing and raising capital, SinglePoint continues to explore high-potential acquisition opportunities to grow and diversify its current holding base. The company also plans to uplist to the OTCQB and become a fully reporting company during the current fiscal year.

The company has engaged Milost Advisors to pursue acquisitions and financing facilities toward funding acquisitions, as well as to provide working capital. Milost Advisors will assist SinglePoint in the acquisition of undervalued companies with annual revenues of at least $50 million, and has already identified potential acquisition targets for the company to consider. Disclaimer

Singlepoint, Inc. Company Blog

Singlepoint, Inc. News:

NetworkNewsWire Announces Publication Discussing Public Companies Poised to Benefit from Rising Demand for Marijuana

SinglePoint Featured on MoneyTV with Donald Baillargeon, 7/14

NetworkNewsWire Announces Publication Discussing Emerging Standouts in the Legalized Marijuana Sector

ORHub, Inc. (ORHB)

The QualityStocks Daily Newsletter would like to spotlight ORHub, Inc. (ORHB). Today, ORHub, Inc. closed trading at $0.67, up 6.35%, on 54,786 volume with 32 trades. The stock’s average daily volume over the past 60 days is 35,080 and its 52-week low/high is $0.20/$2.09.

ORHub, Inc. (ORHB) is a cloud-based software platform designed to transform the business of surgery into a value-based model. The platform empowers care providers at every stage of the surgical process to collaborate, organize, deliver, measure, and reimburse in one intuitive, easy-to-use program. This significantly decreases cost and improves outcomes by eliminating inefficiencies, duplications of effort, and errors and omissions that result from siloed processes in outdated software and poor handoffs from one part of the care process to another.

The need for ORHub is clear. Health care costs are out of control at more than 17% of US GDP, which equates to over $3 trillion per year. With costs rising every year due to an aging population and increasingly expensive treatments, providers are under severe pressure to become more efficient and reduce costs. This is happening because payors are aggressively reducing reimbursements and finally moving away from fee-for-service and toward a performance-based reimbursement system referred to as value-based health care.

Accurately measuring the cost of treating a condition and relating that cost to the patient's outcome is at the heart of value-based health care. Institutions that have adopted this model have reaped savings of 20-40% on their overall cost of care. Unfortunately, today's siloed IT systems are fundamentally at odds with this process. Legacy health care solutions come from a fee-for-service world and have reinforced the problem and produced a system with erratic quality and unsustainable costs. Most health care applications today are incremental improvements on these existing systems or are simple digital implementations of antiquated pen-and-paper processes.

Providers wanting to practice value-based health care need value-based software. ORHub creates a value-based solution that will revolutionize surgical care delivery by tracking the cost of treating a condition from diagnosis to discharge, and tracking outcomes that resulted from that treatment.

In an industry where major IT rollouts traditionally cost millions of dollars and take an average of eighteen months, pilot installations of ORHub have been completed in less than a month. By avoiding integration with legacy systems completely through a radically comprehensive and collaborative approach, providers see results right away. This approach produces real-time metrics in a uniform manner at any institution, which makes it ideal for large providers looking to make improvements across the board at multiple facilities.

ORHub started as a pilot program developed in cooperation with a major Southern California hospital. It has since expanded operations into a second facility at the number two non-profit hospital system in the US. Three additional pilot programs are scheduled prior to a national launch. The company has raised more than $1.6 million as of January 2017.

The company is also a showcase member of the startup program at Microsoft, which has been a key partner by providing financial assistance, strategy, introductions to influencers and mentors, and access to its sales organization who see ORHub as an exciting partner to expand the utilization of Microsoft Surface devices and Azure Cloud. Microsoft is funding a major case study in partnership with Intel about the impact of ORHub on participating institutions to be concluded sometime in Q2 2017.

ORHub's leadership team is helmed by Colt Melby, who was appointed CEO in 2016 and has been crucial to developing and executing the company's business strategy. Mr. Melby's extensive business experience includes the NASDAQ uplisting of Smith and Wesson (now American Outdoor Brands), CUI Global Inc., and Quest Resource Holdings Corp. His wealth of information and relationships have been vital in helping the company go from concept to production in institutional medicine in less than a year.

Delivering surgical care to a single patient is a complex process that may take half a dozen companies and more than a dozen departments cooperating inside and outside the care facility. ORHub simplifies and streamlines this process by enabling vendors, providers, and surgeons to collaborate on providing care. Disclaimer

ORHub, Inc. Blog

ORHub, Inc. News:

ORHub, Inc. Introduces Fourth Medical Software Service Line, Continuing Rapid Expansion Strategy

ORHub, Inc. Executing Aggressive Expansion Strategy with Introduction of Third Service Line

ORHub, Inc. Signs National Deployment Agreement to Roll-out Transformative Medical Software in Major U.S. Markets

Patriot One Technologies, Inc. (PTOTF)

The QualityStocks Daily Newsletter would like to spotlight Patriot One Technologies, Inc. (PTOTF). Today, Patriot One Technologies, Inc. closed trading at $0.641, off by 2.88%, on 11,212 volume with 17 trades. The stock’s average daily volume over the past 60 days is 75,317, and its 52-week low/high is $0.4665/$1.49.

Patriot One Technologies, Inc. (PTOTF) is leveraging seven years of development to create powerful technologies that mitigate security risks by detecting concealed weapons via novel radar technology.

Developed through a NATO-funded project at McMaster University, Patriot One's disruptive NForce CMR1000 technology is the first cost-effective solution available for active shooter prevention, the need for which is evidenced by an increasing number of active shooter events in the United States and worldwide.

A recent study that surveyed data going back as far as 1966 demonstrates that there have been significantly more mass shootings in the U.S. than any other country for decades. Statistics for the 46-year period shows that even though America only holds 5% of the world's population, it took count of 31% of all public mass shootings. According to the FBI, there were an astounding 160 incidents from 2000 to 2013 that resulted in 486 people killed and 557 wounded. In years 2014 and 2015, there were nearly six times as many incidents compared to 2000 and 2001. The disturbing trend shows that there will be increasingly more incidents if better preventative measures aren't taken.

Patriot One's patent-pending solution to this alarming progression enables stand-off detection, even on moving targets, with a "cognitive" ability to learn and identify new threats once deployed. The product is not intended to threaten the constitutional rights of legal gun carriers, and it is also void of privacy and health concerns of traditional detection technologies, which require subject compliance, present false positives, and are often slow, inefficient and costly.

In contrast, Patriot One's technology is small in size and can be "covertly" placed in a doorway or hallway to prevent planned attacks in public places like schools, concerts, stadiums, banks, airports, offices, hospitals, shopping centers and other facilities for which there are concerns. With this method of deployment, there is no subject compliance requirement. In addition, because an image of the target is not generated, there are also no privacy concerns. Detection is real-time and entirely computer-based, which means there is no need for human operators to alert security. This eliminates the safety concerns of a would-be operator, reduces the expense of a human operator, and enables overall accuracy of 93%.

The technology is designed to identify if someone is carrying a gun, knife, suicide vest, etc., by analyzing metal content and relating it to a database of known weapon signatures. Patriot One believes the widespread use of this detection technology could act as an effective deterrent, thereby diminishing the epidemic phenomena of active shooters across the nation and around the world.

The company is guided by a team of experts in the areas of high-frequency electromagnetics, counter-terrorism, conflict resolution, government/corporate interface, sensor development, proactive security and business development. Senior Management has partnered with, among other affiliates, Ridge Global, which was founded by recently appointed advisory board member Tom Ridge, the first head of the Department of Homeland Security, first U.S. Secretary of Homeland Security, and 43rd governor of Pennsylvania.

Along with its partners, Patriot One is addressing global concerns of active shooting events and other violent terrorist attacks. The key is to short-circuit the event through effective prevention technologies and security protocols. Disclaimer

Patriot One Technologies, Inc. Company Blog

Patriot One Technologies, Inc. News:

NetworkNewsWire Releases Exclusive Audio Interview with Patriot One Technologies, Inc. (PTOTF)

Patriot One Initiates Pacific Rim Sales with Aotea Security of New Zealand

Patriot One Marks 3-Months of Global PATSCAN Sales with $2.7M in Signed Agreements

BlastGard International Inc. (BLGA)

The QualityStocks Daily Newsletter would like to spotlight BlastGard International Inc. (BLGA). Today, BlastGard International Inc. closed trading at $0.0153, off by 5.26%, on 38,021 volume with 4 trades. The stock’s average daily volume over the past 60 days is 84,774 and its 52-week low/high is $0.005/$0.03.

BlastGard International Inc. (BLGA) is a manufacturer and distributor of protective products for military and law enforcement personnel. The Corporation operates under two segments, BlastGard Defense Group and Highcom Security.

Blastguard is a blast mitigation specialist with proprietary material proven to effectively mitigate blasts and suppress fires resulting from explosions. The company's patented BlastWrap® technology acts as a "virtual tent" to effectively mitigate blast effects and suppress post-blast fires. This unique technology works by triggering physical and chemical processes to dissipate blast energy, thereby reducing the aftermath of acoustic and shock waves, peak overpressure, reflected peak overpressure, impulse and afterburn. The remaining, significantly reduced energy is transmitted at a slower, more sustainable level. Notably, BlastWrap does not dispense chemical extinguishants; uses neither alarms, sensors, nor an activation system; and is nontoxic and ecologically friendly.

Similarly, the company's BlastGard MTR trash receptacles dramatically reduce lethal threats posed by the detonation of an improvised explosive device (IED). Equipped with Triple Wall Technology, BlastGard MTR mitigates primary fragments, secondary fragments, mechanical effects (shock/blast pressure) and thermal effects (contact and radiation burn) from the fireball, after-burn and resultant post-blast fires.

BlastGard's primary market focus lies on providing blast effects mitigation solutions for customers operating in the commercial sector, military, law enforcement and government agencies. With a vision of being recognized as the leading provider of environmentally responsible solutions to protect lives and structures from the hazards associated with fire and explosions, the company is capable of addressing a wide array of industry applications spanning from fire suppression for naval vessels and merchant ships to protection of buildings against vehicle bombs.

This vision is supported by the ban of Halon extinguishing agents, as outlined in the Montreal protocol, which effectively establishes BlastWrap® as the only blast and fire suppression means available for most applications, including adaptation for underwater use.

The company's position at the head of the blast suppression market has helped BlastGard attain a number of government awards, including designation of its BlastWrap® product as a Qualified Anti-Terrorism Technology and placement on the "Approved Products List for Homeland Security." This designation was extended in early 2017, meaning that BlastWrap® is approved for use by the Department of Homeland Security under the SAFETY Act until November 2021.

HighCom Security, develops, tests, manufactures and distributes body armor and personal protective equipment, including more than two dozen NIJ (National Institute of Justice) compliant hard and soft armor products. Highcom Security has a 20-year history of producing quality armor with no operational failures and no recalls of its American made products.

Highcom Security was founded in 1997 and has produced close to 1 million pieces of armor for the Global community. The company is ISO 9001:2008 certified and the first company in the world to be BA 9000:2012 certified compliant.

For the past decade, Highcom Security has also been able to offer some of the largest armor manufacturers with private label/OEM hard armor solutions for end use by military and law enforcement agencies globally, a market reach obtained because of the company's reputation for innovative technology, exceptional customer service and superior quality performance. Disclaimer

BlastGard International Inc. Blog

BlastGard International Inc. News:

BlastGard International, Inc. (BLGA) Engages NetworkNewsWire for Corporate Communications Solutions

BlastGard International Inc. (BLGA) is “One to Watch”

BlastGard International Addresses Company's Trading Activity


Rate Us
Tell us how we're doing!
Click here to begin your review.

Today's Top 3
Investment Newsletters



(RSRT) +77.22%


(SING) +29.36%


MarketClub Analysis
(SHOR) +28.21%

By The Numbers Charts

The QualityStocks Public Company Sponsor News

Featured Sponsor

Daily Sponsors


The QualityStocks By The Numbers Report

Click the chart below to see the full report

About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market
each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge"
based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.


About Us     Archives     Blog     Clients     Disclaimer     Market Basics    Partners      Quotes & News     Video     Contact Us

twitter icon facebook icon

QualityStocks Logo

Copyright © 2006 - 2012. QualityStocks 3370 N. Hayden Rd., Suite 123-591, Scottsdale, AZ 85251